Cargando…

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

Background: The prognostic role of programmed cell death-ligand 1 (PD-L1) in bladder cancer has been investigated in previous studies, but the results remain inconclusive. Therefore, we carried out a meta-analysis to evaluate the prognostic significance of PD-L1 in patients with bladder cancer. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Lei, Sun, Jin, Wang, Ling, Li, Zhigang, Wang, Lei, Li, Zhibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763705/ https://www.ncbi.nlm.nih.gov/pubmed/31616289 http://dx.doi.org/10.3389/fphar.2019.00962

Ejemplares similares

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis
por: Wang, Shuxia, et al.
Publicado: (2020)

Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis
por: Xie, Qinfen, et al.
Publicado: (2020)

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis
por: Lu, Ling, et al.
Publicado: (2020)

Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis
por: Zheng, Chuanxi, et al.
Publicado: (2018)

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis
por: Wang, Qianqian, et al.
Publicado: (2017)

Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis
por: Shen, Zefeng, et al.
Publicado: (2019)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis
por: Xu, Gang, et al.
Publicado: (2019)

Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis
por: Zeng, Qiang, et al.
Publicado: (2020)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
por: Ding, Xiangli, et al.
Publicado: (2019)

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
por: Zeng, Siyuan, et al.
Publicado: (2023)

Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
por: Dai, Zelei, et al.
Publicado: (2023)

Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis
por: Zhang, Qian, et al.
Publicado: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
por: Chen, Ruo Qiao, et al.
Publicado: (2019)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
por: Zhang, Minghui, et al.
Publicado: (2016)

Clinicopathological and Prognostic Significance of Survivin Over-Expression in Patients with Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Li, Chunguang, et al.
Publicado: (2012)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis
por: Qiu, Liping, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of Ephrin A3 in bladder urothelial carcinoma
por: Wang, Yi-Fan, et al.
Publicado: (2023)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Li, Chao, et al.
Publicado: (2019)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer
por: Li, Jinze, et al.
Publicado: (2022)

Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis
por: Zhu, Hanlong, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder
por: Kim, Donghyun, et al.
Publicado: (2020)

The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
por: Lei, Yu-ying, et al.
Publicado: (2017)

Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis
por: Zhang, Xunlei, et al.
Publicado: (2020)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis
por: Chen, Yifei, et al.
Publicado: (2017)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g9kgr7tbk2vrbp4g1l5m0hmdrl